Skip to content

Replimune Group REPL Total Operating Expenses

Total Operating Expenses at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$30.93M-27.9%
Immunome logo
ImmunomeIMNM
$59.33M+24.7%
Erasca, Inc. logo
Erasca, Inc.ERAS
$187.91M+427%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$81.59M-11.8%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$115.1M+36.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$151M+0.7%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's total operating expenses?
Replimune Group (REPL) reported total operating expenses of $71.87M in Q4 2025.
How has Replimune Group's total operating expenses changed year-over-year?
Replimune Group's total operating expenses increased by 8.9% year-over-year, from $66.02M to $71.87M.
What is the long-term trend for Replimune Group's total operating expenses?
Over 3 years (2022 to 2025), Replimune Group's total operating expenses has grown at a 30.3% compound annual growth rate (CAGR), from $118.31M to $261.63M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.